Effect of acetazolamide on visuomotor performance at high altitude in healthy people 40 years of age or older-RCT.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
08
2022
accepted:
04
01
2023
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Altitude travel is increasingly popular also for middle-aged and older tourists and professionals. Due to the sensitivity of the central nervous system to hypoxia, altitude exposure may impair visuomotor performance although this has not been extensively studied. Therefore, we investigated whether a sojourn at moderately high altitude is associated with visuomotor performance impairments in healthy adults, 40y of age or older, and whether this adverse altitude-effect can be prevented by acetazolamide, a drug used to prevent acute mountain sickness. In this randomized placebo-controlled parallel-design trial, 59 healthy lowlanders, aged 40-75y, were assigned to acetazolamide (375 mg/day, n = 34) or placebo (n = 25), administered one day before ascent and while staying at high altitude (3100m). Visuomotor performance was assessed at 760m and 3100m after arrival and in the next morning (post-sleep) by a computer-assisted test (Motor-Task-Manager). It quantified deviation of a participant-controlled cursor affected by rotation during target tracking. Primary outcome was the directional error during post-sleep recall of adaptation to rotation estimated by multilevel linear regression modeling. Additionally, adaptation, immediate recall, and correct test execution were evaluated. Compared to 760m, assessments at 3100m with placebo revealed a mean (95%CI) increase in directional error during adaptation and immediate recall by 1.9° (0.2 to 3.5, p = 0.024) and 1.1° (0.4 to 1.8, p = 0.002), respectively. Post-sleep recall remained unchanged (p = NS), however post-sleep correct test execution was 14% less likely (9 to 19, p<0.001). Acetazolamide improved directional error during post-sleep recall by 5.6° (2.6 to 8.6, p<0.001) and post-sleep probability of correct test execution by 36% (30 to 42, p<0.001) compared to placebo. In healthy individuals, 40y of age or older, altitude exposure impaired adaptation to and immediate recall and correct execution of a visuomotor task. Preventive acetazolamide treatment improved visuomotor performance after one night at altitude and increased the probability of correct test execution compared to placebo. ClinicalTrials.gov NCT03536520.
Identifiants
pubmed: 36662903
doi: 10.1371/journal.pone.0280585
pii: PONE-D-22-22670
pmc: PMC9858039
doi:
Substances chimiques
Acetazolamide
O3FX965V0I
Banques de données
ClinicalTrials.gov
['NCT03536520']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0280585Informations de copyright
Copyright: © 2023 Reiser et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neurosci Biobehav Rev. 2017 Mar;74(Pt A):225-232
pubmed: 28111267
PLoS One. 2014 Mar 21;9(3):e92191
pubmed: 24658407
Respiration. 2018;95(6):422-432
pubmed: 29502125
Neurotoxicol Teratol. 2013 Jan-Feb;35:28-33
pubmed: 23280141
Front Physiol. 2018 Jun 04;9:677
pubmed: 29915546
Front Physiol. 2016 Jan 06;6:372
pubmed: 26779029
Neuropharmacology. 2017 May 15;118:148-156
pubmed: 28286213
Eur Heart J. 2013 Mar;34(10):759-66
pubmed: 22711752
Chest. 2012 Jan;141(1):131-138
pubmed: 21659435
Aviat Space Environ Med. 1984 Jul;55(7):598-603
pubmed: 6466255
Eur Respir J. 1998 Dec;12(6):1242-7
pubmed: 9877470
J Appl Physiol (1985). 2007 Apr;102(4):1313-22
pubmed: 17023566
Sci Rep. 2018 Sep 24;8(1):14286
pubmed: 30250049
Physiol Behav. 2015 Feb;139:121-6
pubmed: 25449393
Neuropsychol Rev. 2004 Dec;14(4):197-224
pubmed: 15796116
Chest. 2014 Aug;146(2):299-308
pubmed: 24811331
N Engl J Med. 1979 Dec 13;301(24):1329-31
pubmed: 503151
High Alt Med Biol. 2013 Dec;14(4):338-41
pubmed: 24377340
J Appl Physiol (1985). 2015 Dec 15;119(12):1494-500
pubmed: 26472861
Front Physiol. 2018 Aug 21;9:1131
pubmed: 30246787
Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16000-16008
pubmed: 32571910
J Neurosci. 2005 Jan 12;25(2):473-8
pubmed: 15647491
Front Physiol. 2022 Sep 08;13:980755
pubmed: 36160864
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1206-1214
pubmed: 32401069
High Alt Med Biol. 2019 Dec;20(4):361-374
pubmed: 31651199
Nature. 2004 Jul 1;430(6995):78-81
pubmed: 15184907
PLoS One. 2017 Mar 27;12(3):e0174277
pubmed: 28346535
Aviat Space Environ Med. 1983 Dec;54(12 Pt 1):1063-73
pubmed: 6661120